JCR, Modalis expand research partnership for CNS gene therapy
01/06/25, 1:22 PM
Location
tokyoIndustry
genetics
therapeutics
medical
biotechnology
health care
Type
partnership
JCR Pharmaceuticals and Modalis Therapeutics have agreed to proceed to the next phase of their existing research partnership with a new joint research agreement, aiming to develop a novel gene therapy to improve efficacy, safety, and reduce burden through intravenous injection for CNS diseases.
Company Info
Location
tokyo, japan
Additional Info
Modalis Therapeutics develops precision genetic medicines using epigenome editing technology. The company focuses on therapies for orphan genetic diseases leveraging its proprietary CRISPR-GNDM® technology, which enables gene/locus-specific modulation of gene expression without altering the DNA sequence. Modalis is dedicated to bringing life-changing treatments to patients suffering from diseases for which no cure currently exists. With a mission of 'Every Life Deserves Attention,' the company aims to address unmet medical needs in the field of rare diseases.
Unlock Strategic Intelligence with Fundz
Access real-time funding updates, strategic shifts with FundzWatch™, exclusive Family Offices, and more — helping you close deals and seize opportunities faster.
Trusted by sales, BD, and investment teams at Oracle, HubSpot, Affinity, and more.